<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512451941</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512451941</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sinnecker</surname><given-names>Tim</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bozin</surname><given-names>Ivan</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dörr</surname><given-names>Jan</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451941">2</xref>
<xref ref-type="aff" rid="aff3-1352458512451941">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pfueller</surname><given-names>Caspar F</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451941">2</xref>
<xref ref-type="aff" rid="aff3-1352458512451941">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Harms</surname><given-names>Lutz</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512451941">3</xref>
<xref ref-type="aff" rid="aff4-1352458512451941">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Niendorf</surname><given-names>Thoralf</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512451941">2</xref>
<xref ref-type="aff" rid="aff5-1352458512451941">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brandt</surname><given-names>Alexander U</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451941">2</xref>
<xref ref-type="aff" rid="aff3-1352458512451941">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Paul</surname><given-names>Friedemann</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451941">2</xref>
<xref ref-type="aff" rid="aff3-1352458512451941">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wuerfel</surname><given-names>Jens</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451941">1</xref>
<xref ref-type="aff" rid="aff5-1352458512451941">5</xref>
<xref ref-type="aff" rid="aff6-1352458512451941">6</xref>
</contrib>
<aff id="aff1-1352458512451941"><label>1</label>NeuroCure Clinical Research Center, Charité - University Medicine Berlin, Germany</aff>
<aff id="aff2-1352458512451941"><label>2</label>Experimental and Clinical Research Center, Charité - University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany</aff>
<aff id="aff3-1352458512451941"><label>3</label>Clinical and Experimental Multiple Sclerosis Research Center, Charité - University Medicine Berlin, Germany</aff>
<aff id="aff4-1352458512451941"><label>4</label>Department of Neurology, Charité - University Medicine Berlin, Germany</aff>
<aff id="aff5-1352458512451941"><label>5</label>Berlin Ultrahigh Field Facility, Max Delbrueck Center for Molecular Medicine, Germany</aff>
<aff id="aff6-1352458512451941"><label>6</label>Institute of Neuroradiology, University of Luebeck, Germany</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1352458512451941">Friedemann Paul, NeuroCure Clinical Research Center, Charité -University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany. Email: <email>friedemann.paul@charite.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>316</fpage>
<lpage>325</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>9</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512451941">
<title>Background:</title>
<p>Damage to venules in multiple sclerosis was first described decades ago. Today, ultrahigh magnetic field strength T2*-weighted magnetic resonance imaging (MRI) techniques depict very small cerebral veins in vivo with great anatomical detail.</p>
</sec>
<sec id="section2-1352458512451941">
<title>Objective:</title>
<p>We aimed to investigate alterations of periventricular small blood vessel appearance in relation to T2 lesion count and distribution in multiple sclerosis and clinically isolated syndrome in comparison with healthy control subjects at 7 Tesla MRI.</p>
</sec>
<sec id="section3-1352458512451941">
<title>Methods:</title>
<p>We investigated 38 patients (including 16 with early multiple sclerosis and seven with clinically isolated syndrome) and 22 matched healthy controls at 7 Tesla. The protocol included T2*-weighted Fast Low Angle Shot, and T2-weighted Turbo Inversion Recovery Magnitude sequences. We quantified periventricular venous density by a novel region-of-interest-based algorithm, expressing the ratio of ‘veins per region-of-interest’ as well as of ‘periventricular vascular area’.</p>
</sec>
<sec id="section4-1352458512451941">
<title>Results:</title>
<p>Our study revealed significantly decreased venous density in multiple sclerosis patients compared with healthy controls. Venous alterations were already detectable in clinically isolated syndrome and early multiple sclerosis, although to a smaller extent. Venous density correlated inversely with periventricular and whole-brain T2 lesion count. Furthermore, we found no indication for cerebral venous congestion in multiple sclerosis.</p>
</sec>
<sec id="section5-1352458512451941">
<title>Conclusion:</title>
<p>High spatially resolving anatomical T2*-weighted MRI revealed vascular alterations in early stages of multiple sclerosis, presumably as a part of widespread haemodynamic and metabolic alterations.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>MRI</kwd>
<kwd>vascular</kwd>
<kwd>7 Tesla</kwd>
<kwd>brain</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458512451941" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is an inflammatory and degenerative autoimmune disease of the central nervous system with multifactorial pathogenesis.<sup><xref ref-type="bibr" rid="bibr1-1352458512451941">1</xref></sup> In 1916, Dawson described MS lesions as plaques mostly centred on small periventricular veins.<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup> The resulting lesion distribution pattern was later termed ‘Dawson’s fingers’ owing to its periventricular localisation and cockscomb-like appearance in sagittal magnetic resonance imaging (MRI) slices. Consequently, the pathophysiological role of small cerebral venules remains a key issue in MS research, since cell invasion into the brain parenchyma requires extravasation through the endothelium into the perivascular space. Significant damage to these vein walls was reported in early histopathological studies revealing venulitis, thickened vein walls containing fibrinoid and haemosiderin deposition, and a prominent perivascular inflammation.<sup><xref ref-type="bibr" rid="bibr3-1352458512451941">3</xref><xref ref-type="bibr" rid="bibr4-1352458512451941"/>–<xref ref-type="bibr" rid="bibr5-1352458512451941">5</xref></sup></p>
<p>As a result of the rapid improvements of modern imaging techniques, perivascular inflammation and altered perivascular spaces have been detected in vivo using MRI.<sup><xref ref-type="bibr" rid="bibr6-1352458512451941">6</xref>,<xref ref-type="bibr" rid="bibr7-1352458512451941">7</xref></sup> Today, even small intracranial veins can likewise be studied in vivo using high spatial resolution ultrahigh-field MRI. Based on the very high signal-to-noise ratio and increased susceptibility effects, 7 Tesla (7T) T2*-weighted Fast Low Angle Shot (FLASH) images depict small veins with great anatomical distinction, and impressively demonstrate the perivascular setting of MS lesions.<sup><xref ref-type="bibr" rid="bibr8-1352458512451941">8</xref><xref ref-type="bibr" rid="bibr9-1352458512451941"/><xref ref-type="bibr" rid="bibr10-1352458512451941"/><xref ref-type="bibr" rid="bibr11-1352458512451941"/><xref ref-type="bibr" rid="bibr12-1352458512451941"/><xref ref-type="bibr" rid="bibr13-1352458512451941"/><xref ref-type="bibr" rid="bibr14-1352458512451941"/>–<xref ref-type="bibr" rid="bibr15-1352458512451941">15</xref></sup></p>
<p>Given their excellent visibility in T2*-weighted MRI, we developed a novel quantification algorithm for small cerebral veins in a periventricular location. We then investigated (i) whether number and density of periventricular veins in MS and clinically isolated syndrome (CIS) are different from controls; and (ii) whether these measures are related to T2 lesion count and clinical disease status.</p>
</sec>
<sec id="section7-1352458512451941" sec-type="methods">
<title>Methods</title>
<sec id="section8-1352458512451941">
<title>Study participants</title>
<p>We prospectively enrolled 38 patients from the outpatient clinic of the Clinical and Experimental MS Research Centre at the Charité-Universitätsmedizin Berlin, including seven patients with CIS and 28 patients with MS of relapsing–remitting disease course (RRMS), as well as two patients with secondary progressive and one patient with primary progressive disease course fulfilling the current panel diagnostic criteria.<sup><xref ref-type="bibr" rid="bibr16-1352458512451941">16</xref></sup> Neurological disability was assessed with the Kurtzke Expanded Disability Status Scale (EDSS).<sup><xref ref-type="bibr" rid="bibr17-1352458512451941">17</xref></sup> Furthermore, 22 healthy volunteers served as controls (<xref ref-type="table" rid="table1-1352458512451941">Table 1</xref>). The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki in its currently applicable version, the guidelines of the International Conference on Harmonisation of Good Clinical Practice (ICH-GCP) and applicable German laws. All participants gave informed written consent.</p>
<table-wrap id="table1-1352458512451941" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic overview of patients/participants included in the study.</p>
</caption>
<graphic alternate-form-of="table1-1352458512451941" xlink:href="10.1177_1352458512451941-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center">Controls</th>
<th align="center">Patients</th>
<th align="center">CIS</th>
<th align="center">MS</th>
<th align="center">early MS</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>n</bold></td>
<td/>
<td>22</td>
<td>38</td>
<td>7</td>
<td>31</td>
<td>16</td>
</tr>
<tr>
<td><bold>Gender</bold></td>
<td>female [<italic>n</italic>]</td>
<td>10</td>
<td>16</td>
<td>3</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td/>
<td>Chi<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup></td>
<td>.</td>
<td><italic>p</italic>=0.80</td>
<td><italic>p</italic>=0.90</td>
<td><italic>p</italic>=0.80</td>
<td><italic>p</italic>=0.51</td>
</tr>
<tr>
<td><bold>Age</bold></td>
<td>mean±SD,</td>
<td>39±15,</td>
<td>38±10,</td>
<td>26±6,</td>
<td>40±8,</td>
<td>32±9,</td>
</tr>
<tr>
<td/>
<td>range [years]</td>
<td>20–70</td>
<td>19–56</td>
<td>19–35</td>
<td>25–56</td>
<td>19–52</td>
</tr>
<tr>
<td/>
<td><italic>t</italic>-test</td>
<td>.</td>
<td><italic>p</italic>=0.731</td>
<td><italic>p</italic>=0.046</td>
<td><italic>p</italic>=0.653</td>
<td><italic>p</italic>=0.094</td>
</tr>
<tr>
<td><bold>Disease duration</bold></td>
<td>mean±SD,</td>
<td>.</td>
<td>70±80,</td>
<td>8±3,</td>
<td>84±82,</td>
<td>12±7,</td>
</tr>
<tr>
<td/>
<td>range [months]</td>
<td/>
<td>2–312</td>
<td>2–12</td>
<td>6–312</td>
<td>2–24</td>
</tr>
<tr>
<td><bold>EDSS</bold></td>
<td>Median, range</td>
<td>.</td>
<td>1.5, 0.0–7.0</td>
<td>1.0, 0.0–2.0</td>
<td>1.5, 0.0–7.0</td>
<td>1.5, 0.0–4.0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512451941">
<p><bold>Key:</bold> Chi<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup>: Pearson’s Chi<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup> test to assess differences between patient subgroups and controls; <italic>t</italic>-test: Student’s <italic>t</italic>-test to assess differences between patient subgroups and controls; CIS: clinically isolated syndrome; MS: multiple sclerosis; early MS: CIS and MS patients with a disease duration of up to 24 months; SD: standard deviation; EDSS: Expanded Disability Status Scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-1352458512451941">
<title>MRI data acquisition</title>
<p>Ultrahigh-field MR images were acquired using a 7T whole-body MR system (Magnetom, Siemens, Erlangen, Germany), applying a 24-channel receive RF coil tailored for brain imaging (Nova Medical, Wilmington, MA, USA). Involuntary subject movement was suppressed by applying head-fixating cellular material inside the head coil. The imaging protocol included two-dimensional axial T2*-weighted FLASH (TE 25.0 ms; TR 1820 ms; acquisition time 12:11 min, spatial resolution 0.5 × 0.5 × 2 mm) and turbo inversion recovery magnitude (TIRM; TE 90 ms; TR 16000 ms; TI 2925.5 ms, acquisition time 12:50 min, spatial resolution 1.0 × 1.0 × 3.0 mm) sequences.</p>
</sec>
<sec id="section10-1352458512451941">
<title>Quantification algorithm for small cerebral veins</title>
<p>For the quantification of small cerebral veins in a blinded fashion, we developed two independent region-of-interest (ROI)-based analyses (<xref ref-type="fig" rid="fig1-1352458512451941">Figure 1 A</xref>, <xref ref-type="fig" rid="fig1-1352458512451941">B</xref>). For each subject, three continuous axial slices were selected: (i) a slice tangential to the roof of the lateral ventricles; (ii) a slice in parallel and cranial to the first slice; and (iii) a slice in parallel and inferior to the first slice. For analysis a squared ROI (width 1 cm; length 4 cm) was defined between frontal and occipital cornu on each cerebral hemisphere. The caudate vein of Schlesinger was excluded in all analyses in order to focus on small parenchymal veins. This was done against the background of their particular importance to MS pathophysiology.<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup> To avoid double counting of veins in different slices, we only included veins continuously displayed for at least 7 mm (<xref ref-type="fig" rid="fig2-1352458512451941">Figure 2A</xref>) and with kinking of less than 30°. Small parenchymal veins of all ROI were counted in consensus reading of two trained and blinded investigators (TS and JW). Veins per ROI (VPR; [<italic>n</italic>]) were calculated as the number of total veins divided by the number of ROI of each subject.</p>
<fig id="fig1-1352458512451941" position="float">
<label>Figure 1.</label>
<caption>
<p>Venous quantification method.</p>
<p><bold>A. Veins per ROI (VPR).</bold> An axial slice depicting both ventricles is displayed. Two ROIs (orthogonal; width 1 cm, length 4 cm), which include the tangent through the lateral ventricle, were defined to quantify small periventricular veins subsequently. <bold>B. Periventricular vascular area (PVA).</bold> The axial minimal intensity projection map of two slices that barely depict both ventricles is displayed. Within the two ROIs, voxels of small periventricular veins were manually marked with regard to mean signal intensity of normal-appearing vein-free white matter tissue.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451941-fig1.tif"/></fig>
<fig id="fig2-1352458512451941" position="float">
<label>Figure 2.</label>
<caption>
<p>Threshold verification.</p>
<p><bold>A. VPR analysis and multiple counting of veins.</bold> The figure demonstrates the same exemplary vein (arrows) displayed in a cranial (1), and inferior (2) slice. The minimal intensity projection map (3) displays the vein in total (length of vein = 1.05 cm). The 7 mm threshold avoids double counting of the same vein: The venous segment in the cranial slice (1) will be included (length = 0.755 cm). The venous segment in the inferior slice (2) will be excluded.</p>
<p><bold>B, C, D. Impact of different thresholds in PVA analysis.</bold></p>
<p><bold>B. Histogram.</bold> The histogram displays the distribution of signal intensity within one ROI example. A cut-off line indicating 10% of mean signal intensity is plotted. The histogram underlines the results demonstrated in the scatter plot and of the visual analysis showing that a lower threshold dramatically increases the detection of vein-free voxels.</p>
<p><bold>C. Visual analysis.</bold> An initial visual analysis underlines the high sensitivity of the 10% threshold in detecting venous voxels. In contrast, the 5% threshold does not substantially increase the detection of venous voxels, but includes a high proportion of vein-free voxels.</p>
<p><bold>D. Scatter plot.</bold> The scatter plot demonstrates the impact of different thresholds on the periventricular vascular area. The total area of the ROI is 400 mm<sup>2</sup>. The 10% threshold is highly sensitive in detecting venous voxels. The 5% threshold detects more than half of the total ROI area as a vascular area due to the inclusion of a substantial proportion of vein-free voxels.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451941-fig2.tif"/></fig>
<p>Furthermore, we performed an additional analysis quantifying the periventricular vascular area (PVA) indicative for the periventricular venous volume. A minimal intensity projection map (MIP) of two axial T2*-weighted FLASH slices – tangential to the roof of the lateral ventricles – was calculated using OsiriX (OsiriX Foundation, Genève, Switzerland, version 3.8.1). MIP improved the blinding of the examiners through masking a proportion of MS lesions in this area. Importantly, MIP enhanced the detection of voxels containing blood vessels and thus inhibited double counting of veins. Using OsiriX, voxels of small periventricular veins were masked within the bilateral ROI. We included venous voxels expressing a signal intensity lower than 10% of the mean signal intensity of surrounding normal-appearing blood-vessel-free white matter. Finally, the PVA (mm<sup>2</sup>) was calculated.</p>
<p>The applied threshold was determined in a separate analysis, in which various thresholds were compared within a representative dataset (range 25–0%, interval 5%). The 10% value was the best compromise between high sensitivity in detecting venous voxels, and susceptibility in detecting false positive vein-free artefacts. An even lower threshold did not further increase the number of venous voxels; however, it substantially increased the detection of vein-free voxels (<xref ref-type="fig" rid="fig2-1352458512451941">Figure 2 B</xref>–<xref ref-type="fig" rid="fig2-1352458512451941">D</xref>).</p>
</sec>
<sec id="section11-1352458512451941">
<title>Lesion count quantification</title>
<p>In a separate analysis, global T2 lesion count (T2 LC) and periventricular lesion count (PV LC) were assessed using T2*-weighted FLASH and TIRM images. A lesion was defined as hyperintensity relative to the surrounding normal-appearing white or grey matter with a volume of at least three voxels in the T2*-weighted FLASH images and a corresponding hyperintense signal on TIRM. Lesions with a distance of less than 5 mm from the ventricles and a diameter of at least 2 mm were considered as periventricular lesions. Lesions were masked manually using OsiriX integrated ROI functions.</p>
<p>Moreover, all acquired images were analysed with regard to the morphology of veins (appearance; thickness) and MS plaques (perivenous localisation; expression of hypointense rim).</p>
</sec>
<sec id="section12-1352458512451941">
<title>Statistical analysis</title>
<p>Group differences were assessed using an independent two-sample <italic>t</italic>-test for age and Pearson’s Chi<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup> tests (alpha = 0.05) for gender. Patients with CIS and MS with disease duration of up to 24 months were defined as ‘early MS’ (<xref ref-type="table" rid="table1-1352458512451941">Table 1</xref>). A potential gender-related effect on VPR/PVA was analysed using an independent two-sample <italic>t</italic>-test in healthy controls (HC) only. Accordingly, a potential age-related effect on VPR/PVA was investigated using Pearson correlation with VPR/PVA and age as variables in HC.</p>
<p>Group differences between VPR/PVA were assessed using analysis of covariance (ANCOVA) correcting for age.</p>
<p>Association of VPR/PVA with disease measures was analysed and denoted after age correction: an influence of disease duration on VPR/PVA was analysed using a linear regression model with VPR/PVA as dependent and disease duration as independent variable including age as covariate. To analyse a dependency between lesion count and veins, linear regression models were calculated with VPR/PVA as the dependent variable and T2 LC or PV LC as independent variable correcting for age. Residuals from these models were not suggestive for non-linear effects.</p>
<p>To assess intra-rater reliability, VPR in a random sample of 10 HC were rated three times by the same blinded observer with an interval of 3 months. Intra-rater reliability was then calculated as a two-way mixed, average measure intra-class correlation coefficient (ICC) using the consistency model. ICC for the VPR assessment was 0.95 and indicated excellent intra-rater reliability. VPR in a random sample of 10 HC were rated by two blinded observers (TS and IB) in order to estimate the inter-rater reliability. Inter-rater reliability was calculated as a two-way mixed average measure ICC using the consistency model. ICC for VPR assessment was 0.86 and thus indicated good inter-rater reliability.</p>
<p>Statistical analyses were carried out in SPSS (version 20, IBM, Somers, NY, USA); <italic>p</italic>-values &lt; 0.05 were considered significant. All tests should be understood as exploratory data analyses; no previous power calculation and adjustments for multiple testing were performed.</p>
</sec></sec>
<sec id="section13-1352458512451941" sec-type="results">
<title>Results</title>
<p>In total, we detected 1171 lesions in 31 patients with MS and seven patients with CIS (mean ±SD, range: 31 ±30, 1–107) on T2*-weighted FLASH images. Periventricular lesions were most commonly centred by a small blood vessel. In contrast, 15 out of 22 of HC subjects did not present with any detectable brain pathology. Other small white matter lesions – most likely due to microangiopathy – were observed in seven elderly control subjects. These lesions were not centred on a blood vessel.</p>
<sec id="section14-1352458512451941">
<title>No indication for venous congestion</title>
<p>An initial inspection of MR images revealed that small cerebral veins in MS patients with a high lesion count appeared much thinner and reduced in numbers compared with control subjects and patients with lower lesion count. Importantly, there was no indication for periventricular venous congestion in CIS and early MS, predominantly showing normal or reduced values for periventricular venous density (<xref ref-type="fig" rid="fig3-1352458512451941">Figure 3 A</xref>–<xref ref-type="fig" rid="fig3-1352458512451941">D</xref>).</p>
<fig id="fig3-1352458512451941" position="float">
<label>Figure 3.</label>
<caption>
<p>7T T2*-weighted FLASH images of HC, CIS, early MS and RRMS.</p>
<p>Healthy control A (age 29; sex: f) exhibits a representative density of periventricular veins. In CIS patient B (age: 19; sex: m; EDSS 2.0; disease duration 10 months) a normal – but not increased - amount of periventricular veins, and only few white matter lesions (T2 LC = 15) can be detected. Venous density in early MS patient C (age: 25; sex: f; EDSS 1.5; disease duration 21 months, T2 LC = 15) is already decreased, showing no indication for venous congestion. In comparison, MS patient D (age: 50; sex: m; EDSS 1.5; disease duration 168 months) shows a high lesion count (T2 LC = 69) and a substantially reduced number of periventricular veins. In ultrahigh-field T2*-weighted FLASH sequences, MS lesions are often centred by a small blood vessel and frequently express a hypointense rim.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451941-fig3.tif"/></fig>
</sec>
<sec id="section15-1352458512451941">
<title>Group differences</title>
<p>In line with our first impression, quantitative analysis and statistical testing confirmed a decreased number of periventricular veins in MS versus HC as indicated by VPR (<italic>p</italic> &lt; 0.001, <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>, <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>). VPR data are supported by a decreased volume of periventricular veins as indicated by PVA in MS compared with control subjects (<italic>p</italic> &lt; 0.001, <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>, <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>).</p>
<table-wrap id="table2-1352458512451941" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison between patients, subgroups and healthy controls.</p>
</caption>
<graphic alternate-form-of="table2-1352458512451941" xlink:href="10.1177_1352458512451941-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center">Controls</th>
<th align="center">Patients</th>
<th align="center">CIS</th>
<th align="center">MS</th>
<th align="center">early MS</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Periventricular lesion count</bold></td>
<td>mean±SD,</td>
<td>.</td>
<td>14±16,</td>
<td>5±4,</td>
<td>17±17,</td>
<td>9±10,</td>
</tr>
<tr>
<td/>
<td>range [<italic>n</italic>]</td>
<td/>
<td>0–60</td>
<td>0–10</td>
<td>0–60</td>
<td>0–33</td>
</tr>
<tr>
<td><bold>Total lesion count</bold></td>
<td>mean±SD,</td>
<td>.</td>
<td>31±30,</td>
<td>7±7,</td>
<td>36±30,</td>
<td>21±22,</td>
</tr>
<tr>
<td/>
<td>range [<italic>n</italic>]</td>
<td/>
<td>1–107</td>
<td>1–19</td>
<td>1–107</td>
<td>1–72</td>
</tr>
<tr>
<td><bold>Veins per ROI</bold></td>
<td>mean±SD,</td>
<td><bold>7.7</bold>±1.3</td>
<td><bold>5.9</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>§</bold></xref></sup>±2.1</td>
<td><bold>7.0</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>$</bold></xref></sup>±1.5</td>
<td><bold>5.6</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>&amp;</bold></xref></sup>±2.1</td>
<td><bold>6.3</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>#</bold></xref></sup>±1.4</td>
</tr>
<tr>
<td/>
<td>range [<italic>n</italic>]</td>
<td>4.5–10.0</td>
<td>1.0–9.7</td>
<td>4.0–8.0</td>
<td>1.0–9.7</td>
<td>4.0–8.0</td>
</tr>
<tr>
<td><bold>Periventricular vascular area</bold></td>
<td>mean±SD,</td>
<td><bold>77.4</bold>±14.7</td>
<td><bold>54,4</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>§</bold></xref></sup>±18.0</td>
<td><bold>67.8</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>$</bold></xref></sup> 16.6</td>
<td><bold>51.3</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>&amp;</bold></xref></sup>±17.1</td>
<td><bold>58.9</bold><sup><xref ref-type="table-fn" rid="table-fn2-1352458512451941"><bold>#</bold></xref></sup>±17.3</td>
</tr>
<tr>
<td/>
<td>range [mm<sup>2</sup>]</td>
<td>40.7–98.0</td>
<td>15.7–86.2</td>
<td>42.8–86.2</td>
<td>15.7–85.0</td>
<td>40.4–86.2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458512451941">
<p>CIS: clinically isolated syndrome; MS: multiple sclerosis; early MS: CIS and MS patients with a disease duration of up to 24 months; SD: standard deviation; ROI: region of interest; <italic>§ p</italic> &lt; 0.001, ANCOVA correcting for age to assess differences between patients and controls; $ <italic>p</italic> = 0.11 (VPR) and <italic>p</italic> = 0.03 (PVA), ANCOVA correcting for age to assess differences between CIS and controls ; &amp; <italic>p</italic> &lt; 0.001, ANCOVA correcting for age to assess differences between MS and controls; # <italic>p</italic> = 0.001 (VPR) and <italic>p</italic> &lt; 0.001 (PVA), ANCOVA correcting for age to assess differences between early MS and controls.</p></fn>
</table-wrap-foot></table-wrap>
<fig id="fig4-1352458512451941" position="float">
<label>Figure 4.</label>
<caption>
<p><bold>A. Bar chart.</bold> Venous density as indicated by VPR and PVA is significantly (<italic>p</italic> &lt; 0.001) lower in patients versus the control group. VPR and PVA are already decreased in early MS. The reduction of visible veins in CIS was significant for PVA. We observed a good accordance between VPR and PVA. <bold>Key</bold>: VPR: veins per ROI; PVA: periventricular vascular area; n.s.: not significant; * <italic>p</italic> &lt; 0.05; ** <italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001; HC: healthy controls; CIS: clinically isolated syndrome; early MS: MS and CIS patients with a disease duration of up to 24 months; MS: all patients with a definite diagnosis of multiple sclerosis.</p> <p><bold>B, C, D. Linear regression model.</bold> Reduced number of visualised periventricular veins in MS correlates with total (B) and periventricular (C) T2 lesion count and disease duration (D). <bold>Key</bold>: CIS: clinically isolated syndrome; MS: all patients with a definite diagnosis of multiple sclerosis.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451941-fig4.tif"/></fig>
<p>Interestingly, a subgroup analysis revealed a decreased number of small periventricular veins in early MS (<italic>p</italic> = 0.001; <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>), and a tendency to decreased VPR in CIS patients (<italic>p</italic> = 0.11; <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>) when compared with HC.</p>
<p>These abnormalities at the very early stage of the disease were even more pronounced when looking at the periventricular venous volume indicated by PVA. In alignment with the VPR methodology, PVA was already decreased in CIS (<italic>p</italic> = 0.03; <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>), and early MS (<italic>p</italic> &lt; 0.001; <xref ref-type="table" rid="table2-1352458512451941">Table 2</xref>; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>) in comparison with control subjects. In general, we found a high agreement between VPR and PVA (<xref ref-type="fig" rid="fig4-1352458512451941">Figure 4A</xref>).</p>
</sec>
<sec id="section16-1352458512451941">
<title>Association with disease measures</title>
<p>Next, we investigated a possible association of VPR and PVA with the disease measures EDSS, disease duration, periventricular T2 lesion count (PV LC) and global T2 lesion count (T2 LC).</p>
<p>The linear regression model revealed an inverse association between periventricular VPR and T2 LC (<italic>R</italic><sup>2</sup> = 0.631; <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4B</xref>), and PV LC (<italic>R</italic><sup>2</sup> = 0.559; <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4C</xref>).</p>
<p>We found a similar inverse association between PVA and global T2 LC (<italic>R</italic><sup>2</sup> = 0.547; <italic>p</italic> &lt; 0.001) and between PVA and periventricular PV LC (<italic>R</italic><sup>2</sup> = 0.564; <italic>p</italic> &lt; 0.001).</p>
<p>Moreover, our analysis showed a significant inverse correlation between disease duration and periventricular venous density in patients with MS, indicated by VPR (<italic>R</italic><sup>2</sup> = 0.364; <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4D</xref>) and PVA (<italic>R</italic><sup>2</sup> = 0.316; <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig4-1352458512451941">Figure 4D</xref>).</p>
<p>The periventricular venous density also weakly correlated with EDSS (VPR, <italic>R</italic><sup>2</sup> = 0.201; <italic>p</italic> = 0.01; PVA, <italic>R</italic><sup>2</sup> = 0.180; <italic>p</italic> = 0.02).</p>
</sec>
<sec id="section17-1352458512451941">
<title>Venous density in healthy controls</title>
<p>Gender differences in PVA could not be detected in HC (<italic>p</italic> = 0.83). However, the Pearson correlation model revealed that periventricular venous density as defined by PVA was associated with age in HC (PVA, <italic>r</italic> = -0.53, <italic>p</italic> = 0.01).</p>
<p>Looking at the VPR methodology confirmed these results. We did not observe gender differences in VPR in control subjects (<italic>p</italic> = 0.39). In alignment with the PVA analysis, VPR showed a trend towards decreased values of venous density in elderly control subjects (VPR, <italic>r</italic> = -0.39, <italic>p</italic> = 0.07).</p>
</sec></sec>
<sec id="section18-1352458512451941" sec-type="discussion">
<title>Discussion</title>
<p>We utilised the excellent visibility of the venous vasculature on 7T T2*-weighted FLASH images to describe and quantify the periventricular venous density in MS and HC in relation to established disease measures such as T2 lesion count, EDSS and disease duration. Periventricular venous density is already reduced in CIS and early MS. Venous density further decreases as the disease progresses – a relationship that was present irrespective of any age-related effects. Moreover, periventricular venous density shows an inverse association with periventricular or whole-brain T2 lesion count.</p>
<p>Recently, ultrahigh-field MRI was proven to be highly sensitive in detecting venous structures.<sup><xref ref-type="bibr" rid="bibr8-1352458512451941">8</xref><xref ref-type="bibr" rid="bibr9-1352458512451941"/><xref ref-type="bibr" rid="bibr10-1352458512451941"/>–<xref ref-type="bibr" rid="bibr11-1352458512451941">11</xref>,<xref ref-type="bibr" rid="bibr13-1352458512451941">13</xref><xref ref-type="bibr" rid="bibr14-1352458512451941"/>–<xref ref-type="bibr" rid="bibr15-1352458512451941">15</xref></sup> Owing to increased susceptibility effects and a very high spatial resolution, T2*-weighted MRI at 7T MRI impressively visualises the perivenous localisation in every periventricular<sup><xref ref-type="bibr" rid="bibr8-1352458512451941">8</xref></sup> and in the vast majority of all MS lesions.<sup><xref ref-type="bibr" rid="bibr11-1352458512451941">11</xref></sup> In contrast, 1.5T contrast-enhanced MRI venography visualises only major parenchymal veins, and only detects a central vein in up to 45% of MS lesions.<sup><xref ref-type="bibr" rid="bibr18-1352458512451941">18</xref></sup></p>
<p>In 2009, Ge and colleagues published a preliminary 3T MRI study applying susceptibility-weighted imaging (SWI) including 15 patients with RRMS.<sup><xref ref-type="bibr" rid="bibr19-1352458512451941">19</xref></sup> The study was based on an algorithm disregarding small veins and expressing the number of voxels of all visible cerebral veins regardless of their size or localisation. They reported a reduced venous visibility in patients with MS, and an inverse correlation (<italic>r</italic> = -0.6; <italic>p</italic> = 0.02) between the number of ‘venous blood voxels’ and T2 lesion load. Our results are in line with this previous study; however, 7T MRI in our study was benefitted by excellent spatial resolution. Thus, we decided to focus on very small parenchymal periventricular veins, in view of the background of their particular importance in early pathogenesis,<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref></sup> and investigated patients with CIS as well as early MS, applying a novel VPR/PVA algorithm.</p>
<p>Considering the reason for diminished venous vasculature, we agree with previous publications<sup><xref ref-type="bibr" rid="bibr19-1352458512451941">19</xref>,<xref ref-type="bibr" rid="bibr20-1352458512451941">20</xref></sup> that the visibility of veins in MS might be reduced owing to a diminution of deoxygenated venous blood – causing less susceptibility effects and hence less signal loss in T2*/SWI – as part of a widespread hypometabolic disease process in MS, as also demonstrated by positron emission tomography (PET).<sup><xref ref-type="bibr" rid="bibr21-1352458512451941">21</xref>,<xref ref-type="bibr" rid="bibr22-1352458512451941">22</xref></sup></p>
<p>Beyond metabolic considerations, we assume haemodynamic and vascular alterations as additional factors contributing to reduced venous visibility. Recently, haemodynamic alterations have increasingly drawn scientific interest, initiated by a study on venous pathology in MS.<sup><xref ref-type="bibr" rid="bibr23-1352458512451941">23</xref></sup> While increased levels of cerebral blood flow (CBF) and cerebral blood volume (CBV) were reported on acutely inflamed lesions,<sup><xref ref-type="bibr" rid="bibr24-1352458512451941">24</xref></sup> a prolonged mean transit time as well as decreased CBF and CBV are found in chronic disease phases.<sup><xref ref-type="bibr" rid="bibr25-1352458512451941">25</xref><xref ref-type="bibr" rid="bibr26-1352458512451941"/><xref ref-type="bibr" rid="bibr27-1352458512451941"/><xref ref-type="bibr" rid="bibr28-1352458512451941"/>-<xref ref-type="bibr" rid="bibr29-1352458512451941">29</xref></sup> These findings of a reduction in cerebral perfusion were commonly interpreted to be caused by local inflammation and gliosis owing to alterations in the microcirculation, while other groups emphasised the role of astrocytic dysfunction or the consequence of reduced metabolic demand.<sup><xref ref-type="bibr" rid="bibr30-1352458512451941">30</xref>,<xref ref-type="bibr" rid="bibr31-1352458512451941">31</xref></sup> The association of venous density with disease duration may indicate that gliosis during the course of MS is one factor contributing to the reduction of small periventricular veins.</p>
<p>Furthermore, we hypothesise that the involvement of venules in neuroinflammatory processes may directly contribute to the rarefaction of periventricular vein density at 7T, since histological studies report crucial venous damage.<sup><xref ref-type="bibr" rid="bibr3-1352458512451941">3</xref><xref ref-type="bibr" rid="bibr4-1352458512451941"/>-<xref ref-type="bibr" rid="bibr5-1352458512451941">5</xref></sup> Beside perivascular cuffs<sup><xref ref-type="bibr" rid="bibr5-1352458512451941">5</xref></sup> and venulitis,<sup><xref ref-type="bibr" rid="bibr4-1352458512451941">4</xref></sup> intramural fibrinoid deposition, haemosiderin accumulation, and collagenised thickened vein walls not seen in control subjects were correlated with vascular damage.<sup><xref ref-type="bibr" rid="bibr3-1352458512451941">3</xref></sup></p>
<p>Looking at our MS cohort, the inverse correlation between reduced periventricular vein density and T2 LC and disease duration supports the assumption that both pathomechanisms – alteration of perfusion and directly affected venules – may play a causative role.</p>
<p>A further key point of this study was the investigation of very early stages of the disease. Interestingly, our image analysis revealed an already diminished venous vasculature in early MS and CIS patients. Considering the role of the vascular endothelium in leucocyte extravasation and plaque formation,<sup><xref ref-type="bibr" rid="bibr2-1352458512451941">2</xref>,<xref ref-type="bibr" rid="bibr32-1352458512451941">32</xref></sup> and global reduction of white as well as grey matter perfusion already in early stages of MS,<sup><xref ref-type="bibr" rid="bibr26-1352458512451941">26</xref></sup> vascular abnormalities in very early MS have been hypothesised. Our results are in line with an increasing number of studies also reporting widespread diffuse brain parenchymal damage already present in very early MS.<sup><xref ref-type="bibr" rid="bibr33-1352458512451941">33</xref><xref ref-type="bibr" rid="bibr34-1352458512451941"/><xref ref-type="bibr" rid="bibr35-1352458512451941"/><xref ref-type="bibr" rid="bibr36-1352458512451941"/>–<xref ref-type="bibr" rid="bibr37-1352458512451941">37</xref></sup></p>
<p>Nevertheless, in a recent study and in contrast to conclusions we and others<sup><xref ref-type="bibr" rid="bibr19-1352458512451941">19</xref></sup> draw from data on decreased venous density, Zivadinov et al. reported decreased venous visibility on SWI at 3T to be associated with a condition termed chronic cerebrospinal venous insufficiency (CCSVI).<sup><xref ref-type="bibr" rid="bibr20-1352458512451941">20</xref></sup> The authors concluded that decreased venous visibility is a consequence of CCSVI, leading to destruction of small veins during the course of venous congestion and capillary hypertension.<sup><xref ref-type="bibr" rid="bibr20-1352458512451941">20</xref></sup></p>
<p>However, in our opinion, this assumption does not convincingly explain the absence of venous congestion in CIS and very early disease stages as demonstrated in our study, and the absence of increased venous pressure in MS reported by a recent ophthalmo-dynamometry study.<sup><xref ref-type="bibr" rid="bibr38-1352458512451941">38</xref></sup> In line with data from a recent large cohort<sup><xref ref-type="bibr" rid="bibr39-1352458512451941">39</xref></sup> and our own findings,<sup><xref ref-type="bibr" rid="bibr40-1352458512451941">40</xref></sup> we suggest that the disease process in MS causes alterations in cerebral perfusion, impacting cerebral venous visibility on SWI as one of several factors. The extracranial venous outflow might be influenced secondarily as a consequence of a reduced cerebral perfusion. In other words, the proposed condition termed CCSVI may be a consequence of the disease process rather than a causative factor in MS pathogenesis.</p>
<p>A limitation of our study is that we were not able to completely mask all lesions on T2*-weighted FLASH images in the VPR and PVA analysis using MIP, which compromises complete blinding of the examiners to the MS diagnosis. The threshold applied for VPR quantification appeared the best achievable compromise, combining a high sensitivity in detecting veins and avoiding false positives by multiple counting of identical veins. However, this might have decreased our sensitivity in counting small veins. Although any dataset with major subject motion was excluded from this study, motion below the visual detection threshold may still influence our results. Finally, given the strong correlation between VPR and PVA, a high capability of the PVA analysis in detecting venous voxel, a high intra- and inter-rater reliability, the consensus reading of two trained investigators, and their blinding to the clinical data of healthy volunteers and patients (EDSS, disease duration, diagnosis, age, gender, conventional MRI findings), we believe that our results remain robust.</p>
<p>In summary, 7T T2*-weighted FLASH imaging is highly sensitive for the quantification of small periventricular veins and reveals an already reduced periventricular vein density in CIS and early MS compared with matched HC. We demonstrate that the reduction of visualised veins is associated with disease severity given by the total and periventricular T2 LC, as well as disease duration. We propose parenchymal hypoperfusion resulting from local inflammatory damage, widespread hypometabolism and gliosis, as well as a direct venous involvement in the autoimmune disease process to cause a rarefaction of visible periventricular veins in MS.</p>
</sec>
</body>
<back>
<ack><p>We thank our study nurses and technicians Cordula Rudolph, Franziska Lipske, Antje Els and Susan Pikol for excellent support.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by the German Research Foundation (DFG Exc 257).</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>Tim Sinnecker, Ivan Bozin and Prof. Dr. Thoralf Niendorf report no disclosures. Dr Jan Dörr received research grants by Novartis and Bayer Vital, travel support by Novartis, and speaker honoraria by Bayer Vital and Novartis. Dr Dörr is supported by the German Research Foundation (Exc 257). Caspar F Pfueller has received travel grants from Teva Pharmaceuticals Inc. Caspar F Pfueller is supported by the German Research Foundation (Exc 257). Prof Dr Lutz Harms has received speaker honoraria from Biogen, Bayer Healthcare, Novartis, Merck-Serono and Talecris. He serves on the advisory board for Biomarin and has received research support from Biogen and Bayer Healthcare. Alexander U Brandt is cofounder and director of gfnmediber GmbH, has received speaker honoraria from Heidelberg Engineering and travel grants from Biogen Idec. Prof Dr Friedemann Paul has received speaker honoraria, travel grants and research grants from Teva/SanofiAventis, Bayer Schering, MerckSerono, Biogen Idec and Novartis. Prof Dr Paul is supported by the German Research Foundation (Exc 257). Dr Jens Wuerfel serves for the Novartis advisory board.</p></fn>
<fn fn-type="other">
<label>Authors’ contributions</label>
<p>All authors designed and coordinated the study. TS drafted the manuscript. All authors revised the manuscript. TS, IB and JW analysed MRI data. TS and AUB performed the statistical analysis. JD, CFP and FP clinically assessed the patients. TS, JD, CFP and FP performed MRI. All authors provided important intellectual content in preparation of the trial and the manuscript.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512451941">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Compston</surname><given-names>A</given-names></name>
<name><surname>Coles</surname><given-names>A.</given-names></name>
</person-group> <article-title>Multiple sclerosis</article-title>. <source>Lancet</source> <year>2008</year>; <volume>372</volume>: <fpage>1502</fpage>–<lpage>1517</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512451941">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>J.</given-names></name>
</person-group> <article-title>The histology of disseminated sclerosis</article-title>. <source>Trans Roy Soc Edinb</source> <year>1916</year>; <volume>50</volume>: <fpage>517</fpage>.</citation>
</ref>
<ref id="bibr3-1352458512451941">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adams</surname><given-names>CW.</given-names></name>
</person-group> <article-title>Perivascular iron deposition and other vascular damage in multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1988</year>; <volume>51</volume>: <fpage>260</fpage>–<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512451941">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adams</surname><given-names>CW</given-names></name>
<name><surname>Poston</surname><given-names>RN</given-names></name>
<name><surname>Buk</surname><given-names>SJ</given-names></name><etal/>
</person-group>. <article-title>Inflammatory vasculitis in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>1985</year>; <volume>69</volume>: <fpage>269</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512451941">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>R</given-names></name>
<name><surname>Iwasaki</surname><given-names>Y</given-names></name>
<name><surname>Koprowski</surname><given-names>H.</given-names></name>
</person-group> <article-title>Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain</article-title>. <source>Am J Pathol</source> <year>1975</year>; <volume>81</volume>: <fpage>467</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512451941">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y</given-names></name>
<name><surname>Law</surname><given-names>M</given-names></name>
<name><surname>Herbert</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Prominent perivenular spaces in multiple sclerosis as a sign of perivascular inflammation in primary demyelination</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2005</year>; <volume>26</volume>: <fpage>2316</fpage>–<lpage>2319</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512451941">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wuerfel</surname><given-names>J</given-names></name>
<name><surname>Haertle</surname><given-names>M</given-names></name>
<name><surname>Waiczies</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Perivascular spaces – MRI marker of inflammatory activity in the brain?</article-title> <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>2332</fpage>–<lpage>2340</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512451941">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kollia</surname><given-names>K</given-names></name>
<name><surname>Maderwald</surname><given-names>S</given-names></name>
<name><surname>Putzki</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2009</year>; <volume>30</volume>: <fpage>699</fpage>–<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512451941">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tallantyre</surname><given-names>EC</given-names></name>
<name><surname>Brookes</surname><given-names>MJ</given-names></name>
<name><surname>Dixon</surname><given-names>JE</given-names></name><etal/>
</person-group>. <article-title>Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI</article-title>. <source>Neurology</source> <year>2008</year>; <volume>70</volume>: <fpage>2076</fpage>–<lpage>2078</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512451941">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tallantyre</surname><given-names>EC</given-names></name>
<name><surname>Dixon</surname><given-names>JE</given-names></name>
<name><surname>Donaldson</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>534</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512451941">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tallantyre</surname><given-names>EC</given-names></name>
<name><surname>Morgan</surname><given-names>PS</given-names></name>
<name><surname>Dixon</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. <article-title>A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions</article-title>. <source>Invest Radiol</source> <year>2009</year>; <volume>44</volume>: <fpage>491</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512451941">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sinnecker</surname><given-names>T</given-names></name>
<name><surname>Mittelstaedt</surname><given-names>P</given-names></name>
<name><surname>Dörr</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis lesions and irreversible brain tissue damage</article-title>. <source>Arch Neurol</source>. <comment>Epub ahead of print 20 February 2011</comment>. DOI: 10.1001/archneurol.2011.2450<pub-id pub-id-type="doi">10.1001/archneurol.2011.2450</pub-id>.</citation>
</ref>
<ref id="bibr13-1352458512451941">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y</given-names></name>
<name><surname>Zohrabian</surname><given-names>VM</given-names></name>
<name><surname>Grossman</surname><given-names>RI.</given-names></name>
</person-group> <article-title>Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2008</year>; <volume>65</volume>: <fpage>812</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512451941">
<label>14.</label>
<citation citation-type="journal">
<person-group>
<name><surname>Wuerfel</surname><given-names>J</given-names></name>
<name><surname>Sinnecker</surname><given-names>T</given-names></name>
<name><surname>Ringelstein</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis</article-title>. <source>Mult Scler</source> <year>in press</year>.</citation>
</ref>
<ref id="bibr15-1352458512451941">
<label>15.</label>
<citation citation-type="journal">
<person-group>
<name><surname>Sinnecker</surname><given-names>T</given-names></name>
<name><surname>Dörr</surname><given-names>J</given-names></name>
<name><surname>Pfueller</surname><given-names>C</given-names></name>
</person-group>. <article-title>Distinct lesion morphology at 7T MRI differentiates neuromyelitis optica from multiple sclerosis</article-title>. <source>Neurology</source> <year>in press</year>.</citation>
</ref>
<ref id="bibr16-1352458512451941">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512451941">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF.</given-names></name>
</person-group> <article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512451941">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>IL</given-names></name>
<name><surname>van Schijndel</surname><given-names>RA</given-names></name>
<name><surname>Pouwels</surname><given-names>PJ</given-names></name><etal/>
</person-group>. <article-title>MR venography of multiple sclerosis</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2000</year>; <volume>21</volume>: <fpage>1039</fpage>–<lpage>1042</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512451941">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y</given-names></name>
<name><surname>Zohrabian</surname><given-names>VM</given-names></name>
<name><surname>Osa</surname><given-names>EO</given-names></name>
<etal/>
</person-group>. <article-title>Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla</article-title>. <source>J Magn Reson Imaging</source> <year>2009</year>; <volume>29</volume>: <fpage>1190</fpage>–<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512451941">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Poloni</surname><given-names>GU</given-names></name>
<name><surname>Marr</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency</article-title>. <source>BMC Neurol</source> <year>2011</year>; <volume>11</volume>: <fpage>128</fpage>.</citation>
</ref>
<ref id="bibr21-1352458512451941">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<name><surname>Miletich</surname><given-names>RS</given-names></name>
<name><surname>Kinkel</surname><given-names>PR</given-names></name>
<etal/>
</person-group>. <article-title>High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis</article-title>. <source>J Neuroimaging</source> <year>1998</year>; <volume>8</volume>: <fpage>228</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512451941">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blinkenberg</surname><given-names>M</given-names></name>
<name><surname>Rune</surname><given-names>K</given-names></name>
<name><surname>Jensen</surname><given-names>CV</given-names></name>
<etal/>
</person-group>. <article-title>Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS</article-title>. <source>Neurology</source> <year>2000</year>; <volume>54</volume>: <fpage>558</fpage>-<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512451941">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wakefield</surname><given-names>AJ</given-names></name>
<name><surname>More</surname><given-names>LJ</given-names></name>
<name><surname>Difford</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemical study of vascular injury in acute multiple sclerosis</article-title>. <source>J Clin Pathol</source> <year>1994</year>; <volume>47</volume>: <fpage>129</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512451941">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wuerfel</surname><given-names>J</given-names></name>
<name><surname>Bellmann-Strobl</surname><given-names>J</given-names></name>
<name><surname>Brunecker</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study</article-title>. <source>Brain</source> <year>2004</year>; <volume>127</volume>: <fpage>111</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512451941">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zamboni</surname><given-names>P</given-names></name>
<name><surname>Menegatti</surname><given-names>E</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report</article-title>. <source>BMC Med</source> <year>2011</year>; <volume>9</volume>: <fpage>22</fpage>.</citation>
</ref>
<ref id="bibr26-1352458512451941">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varga</surname><given-names>AW</given-names></name>
<name><surname>Johnson</surname><given-names>G</given-names></name>
<name><surname>Babb</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>282</volume>: <fpage>28</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512451941">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adhya</surname><given-names>S</given-names></name>
<name><surname>Johnson</surname><given-names>G</given-names></name>
<name><surname>Herbert</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T</article-title>. <source>Neuroimage</source> <year>2006</year>; <volume>33</volume>: <fpage>1029</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512451941">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y</given-names></name>
<name><surname>Law</surname><given-names>M</given-names></name>
<name><surname>Johnson</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2005</year>; <volume>26</volume>: <fpage>1539</fpage>–<lpage>1547</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512451941">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Law</surname><given-names>M</given-names></name>
<name><surname>Saindane</surname><given-names>AM</given-names></name>
<name><surname>Ge</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter</article-title>. <source>Radiology</source> <year>2004</year>; <volume>231</volume>: <fpage>645</fpage>–<lpage>652</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512451941">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Haeseleer</surname><given-names>M</given-names></name>
<name><surname>Cambron</surname><given-names>M</given-names></name>
<name><surname>Vanopdenbosch</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Vascular aspects of multiple sclerosis</article-title>. <source>Lancet Neurol</source> <year>2011</year>; <volume>10</volume>: <fpage>657</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512451941">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wuerfel</surname><given-names>J</given-names></name>
<name><surname>Paul</surname><given-names>F</given-names></name>
<name><surname>Zipp</surname><given-names>F.</given-names></name>
</person-group> <article-title>Cerebral blood perfusion changes in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2007</year>; <volume>259</volume>: <fpage>16</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512451941">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holman</surname><given-names>DW</given-names></name>
<name><surname>Klein</surname><given-names>RS</given-names></name>
<name><surname>Ransohoff</surname><given-names>RM.</given-names></name>
</person-group> <article-title>The blood-brain barrier, chemokines and multiple sclerosis</article-title>. <source>Biochim Biophys Acta</source> <year>2011</year>; <volume>1812</volume>: <fpage>220</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512451941">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Bozzali</surname><given-names>M</given-names></name>
<name><surname>Rovaris</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis</article-title>. <source>Brain</source> <year>2003</year>; <volume>126</volume>: <fpage>433</fpage>–<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512451941">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rovaris</surname><given-names>M</given-names></name>
<name><surname>Gambini</surname><given-names>A</given-names></name>
<name><surname>Gallo</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution</article-title>. <source>Neurology</source> <year>2005</year>; <volume>65</volume>: <fpage>1626</fpage>–<lpage>1630</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512451941">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sbardella</surname><given-names>E</given-names></name>
<name><surname>Tomassini</surname><given-names>V</given-names></name>
<name><surname>Stromillo</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. <article-title>Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1432</fpage>–<lpage>1440</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512451941">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van</surname><given-names>Au</given-names></name>
<name><surname>Duong</surname><given-names>M</given-names></name>
<name><surname>Audoin</surname><given-names>B</given-names></name>
<name><surname>Le Fur</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study</article-title>. <source>J Neurol</source> <year>2007</year>; <volume>254</volume>: <fpage>914</fpage>–<lpage>923</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512451941">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forn</surname><given-names>C</given-names></name>
<name><surname>Rocca</surname><given-names>M</given-names></name>
<name><surname>Valsasina</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Functional magnetic resonance imaging correlates of cognitive performance in patients with a clinically isolated syndrome suggestive of multiple sclerosis at presentation: an activation and connectivity study</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>153</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512451941">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer-Schwickerath</surname><given-names>R</given-names></name>
<name><surname>Haug</surname><given-names>C</given-names></name>
<name><surname>Hacker</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Intracranial venous pressure is normal in patients with multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>637</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512451941">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Marr</surname><given-names>K</given-names></name>
<name><surname>Cutter</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>138</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512451941">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doepp</surname><given-names>F</given-names></name>
<name><surname>Wurfel</surname><given-names>JT</given-names></name>
<name><surname>Pfueller</surname><given-names>CF</given-names></name>
<etal/>
</person-group>. <article-title>Venous drainage in multiple sclerosis: A combined MRI and ultrasound study</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>1745</fpage>–<lpage>1751</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>